The clinical core is responsible for ascertainment of new target patients, maintenance of the current registry, identification and examination of survivors of two previously established cohorts, recruitment of normal young and elderly Chamorros, clinical examinations, autopsies, collection of blood and CSF specimens and storage, and shipment of specimens to New York (Core C), Seattle (Project 3), and Philadelphia (Project 4). Besides providing excellent clinical characterization of patients and normal controls, Core B. either directly or indirectly, contributes specifically to Core C and all projects. The overall administration will be located at UCSD in San Diego and the Gleam research team will be located at the University of Guam. Dr. Ulla Craig will coordinate all activities on Guam unda the supervision of the principal investigator. New potential target cases will be identified through a screening system of all major health care provides, nursing homes, public health department, and each village mayor's office. Autopsies will be performed at Guam Memorial Hospital, in the Chief Medical Examiner's office, and at the Navy Hospital. Except for the necrologic examinations of patients and normal subjects, all other examinations will be performed by professional staff fluent in Chamorro. Neurologic examinations will be done by board certified neurologists, including the principal investigator, who will spend additional time on the island to supervise all activities and for liaison purposes to health care providers, public health department, University of Guam staff and government offices.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program Projects (P01)
Project #
5P01AG014382-03
Application #
6295654
Study Section
Project Start
1999-03-01
Project End
2000-02-29
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
3
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of California San Diego
Department
Type
DUNS #
077758407
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Dombroski, Beth A; Galasko, Douglas R; Mata, Ignacio F et al. (2013) C9orf72 hexanucleotide repeat expansion and Guam amyotrophic lateral sclerosis-Parkinsonism-dementia complex. JAMA Neurol 70:742-5
Brunden, Kurt R; Ballatore, Carlo; Lee, Virginia M-Y et al. (2012) Brain-penetrant microtubule-stabilizing compounds as potential therapeutic agents for tauopathies. Biochem Soc Trans 40:661-6
Lee, Virginia M-Y; Brunden, Kurt R; Hutton, Michael et al. (2011) Developing therapeutic approaches to tau, selected kinases, and related neuronal protein targets. Cold Spring Harb Perspect Med 1:a006437
Yu, Chang-En; Bird, Thomas D; Bekris, Lynn M et al. (2010) The spectrum of mutations in progranulin: a collaborative study screening 545 cases of neurodegeneration. Arch Neurol 67:161-70
Brunden, Kurt R; Ballatore, Carlo; Crowe, Alex et al. (2010) Tau-directed drug discovery for Alzheimer's disease and related tauopathies: a focus on tau assembly inhibitors. Exp Neurol 223:304-10
Crowe, Alex; Huang, Wenwei; Ballatore, Carlo et al. (2009) Identification of aminothienopyridazine inhibitors of tau assembly by quantitative high-throughput screening. Biochemistry 48:7732-45
Brunden, Kurt R; Trojanowski, John Q; Lee, Virginia M-Y (2009) Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies. Nat Rev Drug Discov 8:783-93
Snyder, L R; Cruz-Aguado, R; Sadilek, M et al. (2009) Lack of cerebral bmaa in human cerebral cortex. Neurology 72:1360-1
Choi, Yoonha; Wijsman, Ellen M; Weir, Bruce S (2009) Case-control association testing in the presence of unknown relationships. Genet Epidemiol 33:668-78
Sieh, Weiva; Choi, Yoonha; Chapman, Nicola H et al. (2009) Identification of novel susceptibility loci for Guam neurodegenerative disease: challenges of genome scans in genetic isolates. Hum Mol Genet 18:3725-38

Showing the most recent 10 out of 53 publications